Effect of Periodontal Therapy on Crevicular Fluid Interleukin-6 and Interleukin-8 Levels in Chronic Periodontitis

Table 5

Concentration and total amount of IL-6 and IL-8 in GCF as well as PD, CAL prior to and following therapy in diseased and nondiseased sites of 7 smokers and 5 nonsmoker periodontal patients.

Parameters	Baseline; (Mean ± SD)	6 weeks; (Mean ± SD)	16 weeks; (Mean ± SD)	32 weeks; (Mean ± SD)
Diseased sites
IL-6 NS	15.85±6.03	43.16±11.86	32.50±13.32	45.57±12.44
IL-6 S	8.19±2.35	26.70±7.69	33.57±11.67	33.82±10.91
TAIL-6 NS	1.46±0.57	1.38±0.43^∗	1.12±0.29	1.52±0.39^∗
TAIL-6 S	0.78±0.28	0.53±0.20^∗	0.56±0.22	0.68±0.17^∗
IL-8 NS	1177.12±496.41	1168.81±509.83	1237.93±337.84	1167.10±305.47
IL-8 S	1051.36±501.22^##	2739.87±823.54^##	4675.88±1062.09	4807.16±938.66
TAIL-8 NS	118.89±44.51	42.67±17.18	40.66±11.31	41.63±9.87^∗
TAIL-8 S	78.80±27.04	71.83±30.45	78.32±19.96	92.52±20.94^∗
PD-NS	6.03±0.81	3.67±1.03	3.30±0.79	3.27±1.05^∗
PD-S	7.52±1.85	3.95±1.25	3.57±1.06	3.79±1.02^∗
CAL-NS	7.10±1.40	5.53±1.61	5.03±1.63	5.13±1.61^∗
CAL-S	7.52±1.85	6.21±2.08	5.95±2.05	6.19±1.81^∗
Nondiseased sites
IL-6 NS	102.46±41.36	92.23±42.07	46.46±12.53	106.38±27.89
IL-6 S	62.97±27.26	75.74±17.89	84.03±22.75	84.53±20.11
TAIL-6 NS	1.93±0.62	1.22±0.41	1.20±0.36	1.77±0.48
TAIL-6 S	1.01±0.41	0.79±0.20	0.84±0.18	0.88±0.30
IL-8 NS	6010.00±2028.23^∗∗##	2656.83±1001.99^∗	1624.08±337.90^∗∗	2542.74±679.54^∗∗
IL-8 S	2491.06±793.85^∗∗##	7523.77±2898.40^∗	6158.88±1095.12^∗∗	6228.52±1809.06^∗∗
TAIL-8 NS	178.59±53.09^∗∗	36.98±11.87^∗	35.49±8.06	41.89±10.04
TAIL-8 S	47.24±21.38^∗∗	73.20±27.11^∗	60.64±11.23	64.29±17.43
PD-NS	2.30±0.67	2.10±0.32	2.00±0.00^∗	2.00±0.47^∗
PD-S	2.50±0.52	2.21±0.70	2.50±0.52^∗	2.50±0.52^∗
CAL-NS	3.20±1.03	3.20±1.03	3.40±0.97	3.40±0.84
CAL-S	3.57±1.45	3.86±1.23	4.00±1.18	3.71±1.33

NS: nonsmokers; S: smokers, IL-6, IL-8: concentration (pg/𝜇L); TAIL-6, TAIL-8: total amount (pg/30 s);
^∗𝑃<0.05 between smokers and nonsmokers.
^∗∗𝑃<0.01 between smokers and nonsmokers.
^##𝑃<0.01 between two examination intervals.